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Summary 
The increasing use of the 7-valent pneumococcal conjugate vaccine has been 
accompanied by the rise of nonvaccine serotypes colonizing the human 
nasopharynx. The vast majority of infections are caused by microorganisms that 
grow in biofilms. It has recently been shown that the formation of Streptococcus 
pneumoniae biofilms in vivo and in vitro is hindered by the presence of capsular 
polysaccharide. The biofilm-forming capacity of pneumococcal clinical isolates 
with different types of capsular polysaccharide and various isogenic transformants 
was examined. Strains of serotypes 19A and 19F, but not 19B and 19C, formed 
≥80% of the quantity of biofilm associated with a non-encapsulated control strain. 
Strains of serogroup 6 also showed significant biofilm-forming capacity. The 
capsules of serotypes 19A and 19F and serogroup 6 contain the disaccharides -D-
Glcp-(1→2)--L-Rhap-(1→ and -D-Glcp-(1→3)--L-Rhap-(1→. Serotype 18A 
and serotypes 18B/18C have very similar capsular disaccharides: -D-GlcpNAc-
(1→3)--L-Rhap-(1→ and -D-Glcp-(1→3)--L-Rhap-(1→, respectively. However, 
the strains of serogroup 18 showed impaired biofilm formation. These results 
indicate that the chemical composition/structure of the capsular polysaccharide is 
crucial to the biofilm-forming capacity of pneumococcal serotypes. Testing of the 
in vitro biofilm-forming ability of isogenic transformants expressing different 
capsular polysaccharides may help predict the emergence of colonizing, 
nonvaccine serotypes. 
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Introduction 
Streptococcus pneumoniae (pneumococcus) is responsible for episodes of acute otitis 
media (AOM), pneumonia, bacteraemia and meningitis, mainly in children, the elderly 
and the immunocompromised, and may be directly responsible for as many child deaths 
as HIV/AIDS, malaria and tuberculosis combined (O'Brien et al., 2009). The 23-valent 
pneumococcal polysaccharide vaccine (PPSV23), introduced in 1983, is recommended 
for all adults aged 65 years and older or adults younger than age 65 years with chronic 
lung disease, chronic cardiovascular diseases, cirrhosis, diabetes mellitus, functional or 
anatomic asplenia, etc., as well as for children over 2 years of age who were at a 
substantially increased risk of developing pneumococcal infection (Centers for Disease 
Control and Prevention (CDC), 2013). A 7-valent conjugate vaccine (PCV7) was 
recommended for universal use in children aged 23 months and younger in the United 
States in 2000 (American Academy of Pediatrics  Committee on Infectious Diseases, 
2000). In the following years its use began in Europe (2001) and other parts of the 
world. PCV7 contains conjugate capsular polysaccharide directed at 7 (4, 6B, 9V, 14, 
18C, 19F and 23F). Since 2000, the widespread use of PCV7 for children has reduced 
the incidence of pneumococcal disease in all age groups (Whitney et al., 2003). A few 
years after its introduction, the rates of AOM and invasive pneumococcal disease (IPD) 
caused by PCV7 serotypes in children under 5 decreased dramatically (Nuorti et al., 
2010). 
It is now clear, however, that the pneumococcal population has changed since the 
widespread introduction of PCV7. Non-PCV7 serotype isolates have increased among 
asymptomatic carriers in a process known as “serotype replacement” and have become 
increasingly responsible for cases of IPD (Weinberger et al., 2011). Although some 
PCV7 serotypes appear to offer cross-protection against certain non-PCV7 serotypes, 
e.g., 6B offers protection against 6A, this has not been clearly demonstrated for 19F and 
19A (Hausdorff et al., 2010). Indeed, the incidence of infections caused by 
multiresistant 19A pneumococci has increased since PCV7 vaccination became 
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common (Liñares et al., 2010; Richter et al., 2013). In the pre-PCV7 era, 19F and 19A 
were among the most common serotypes involved in AOM worldwide (Rodgers et al., 
2009). Nowadays, multiresistant S. pneumoniae 19A isolates remain the most 
commonly encountered in many countries, while the number of 19F infections has 
greatly diminished (Hanage et al., 2011; Spijkerman et al., 2011). Evidence that 
serotype 19A is well capable of colonizing the nasopharynx and causing AOM has 
recently been reported using a chinchilla otitis media model (Laufer et al., 2010). The 
explanation for the notable colonizing capacity of serotypes 19F and 19A remains 
unclear, although a direct relationship between the success of a serotype during 
nasopharyngeal carriage and its capsular polysaccharide (CPS) biochemistry has been 
suggested (Weinberger et al., 2009). It has also been reported that CPS biosynthesis 
interferes with pneumococcal growth in a nutritionally limited environment (as the 
nasopharynx is thought to be), probably by competition for energy with the organism’s 
central metabolism. This suggests that the serotype-specific nasopharyngeal carriage 
prevalence in vivo is predicted by the growth phenotype (Hathaway et al., 2012). 
The vast majority of infections are now thought to be caused by microorganisms 
growing as part of a biofilm (Wolcott and Ehrlich, 2008). A biofilm is a thin layer of 
microorganisms embedded in an extracellular matrix that adheres to the surface of an 
organic or inorganic structure. Recent reports have documented the in vivo formation of 
S. pneumoniae biofilms on adenoid and mucosal epithelial tissues in children with 
recurrent or chronic ear infections (for a recent review, see (Domenech et al., 2012). A 
number of laboratories have also shown that both the in vivo and in vitro formation of 
pneumococcal biofilms is hindered by the presence of CPS, i.e., the presence of a 
capsule inhibits pneumococcal biofilm development (Domenech et al., 2012). Indeed, 
encapsulated clinical pneumococcal isolates and isogenic transformants form 
significantly less biofilm than non-encapsulated strains (Moscoso et al., 2006), and an 
inverse relationship is reported between the ability of non-encapsulated variants to form 
biofilms and the amount of CPS they produce (Domenech et al., 2009). These results 
agree with the proposal that pneumococci regulate CPS expression in their transition 
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from nasopharyngeal carriage associated with biofilm development to IPD 
(Hammerschmidt et al., 2005).  
In contrast to that previously thought, this paper reports that clinical isolates of 
serotypes 19F and 19A (but not 19B or 19C), as well as isogenic transformants 
expressing the CPS of 19F or 19A, are good biofilm producers. This may explain the 
prevalence of these serotypes in the human nasopharynx. Studies with other serogroups 
suggest that the presence of a specific disaccharide in the CPS may be important for 
promoting biofilm formation. 
Results 
Biofilm-forming capacity of serogroup 19 strains 
S. pneumoniae serogroup 19 is composed of four cross-reacting serotypes: 19F, 19A, 
19B and 19C (the latter two seldom cause disease). The repeating units of the 19F and 
19A CPSs are very similar to those of 19B and 19C, although the last two have some 
extra sugars (Fig. 1), and the immunochemical similarities of all four inferred from 
cross-reactivity with factor typing sera (Beynon et al., 1992). As expected, the 
complexity of their chemical structures is reflected in that of the corresponding capsular 
gene clusters (Beynon et al., 1992). The immunological cross-reactions revealed by the 
capsular reaction showed that serotypes 7B, 7C, 19B, 19C, 24F, 24B and 40 have a 
common antigenic determinant known as 7h (Henrichsen, 1995). Comparisons with the 
primary structures of serotypes 19B and 19C agree with a previous proposal (Beynon et 
al., 1992) that the 7h antigen corresponds to the disaccharide element -D-Ribf-(1→4)-
-L-Rhap-(1→ (Fig. 1).  
Figure 2 shows the biofilm-forming capacity of different serogroup 19 isolates. With 
the exception of strains SSISP19F/1, G54 and 1061, which were intermediate biofilm 
formers, most clinical strains of serotypes 19F and 19A formed 80% of the quantity of 
biofilm produced by the nonencapsulated control strain M11. As expected, strain P015 
(a serotype 23F transformant of M11 included as an additional control) formed very 
 6 
little biofilm. In sharp contrast with serotype 19F and 19A strains, those belonging to 
the rare serotypes 19B and 19C behaved like most encapsulated pneumococci, 
producing only a small number of biofilm-associated sessile cells. 
Given the reported inhibitory effect of CPS on biofilm formation, the biofilm-forming 
behavior of the 19F and 19A clinical isolates was unexpected. However, S. pneumoniae 
isolates show wide genetic variability beyond that of CPS formation (Croucher et al., 
2011), and the genetic background of an isolate may strongly influence its capacity to 
form a biofilm (Domenech et al., 2012). To reduce the influence of genetic variability, 
isogenic capsular transformants producing serogroup 19 capsules were constructed 
using the nonencapsulated M11 strain as a recipient (Table 1). The biofilm-forming 
capacity of the corresponding transformants almost paralleled those of the 
corresponding parental clinical isolates (Fig. 2). Notably, strain P192 formed much 
more biofilm than its parent G54, confirming the importance of genetic background in 
biofilm development.  
The distinctive biofilm-forming behavior of the 19F isolates was further examined by 
construction of strain P194, a binary encapsulated transformant of strain P192 that 
simultaneously expressed the CPS of serotypes 19F and 37. Pneumococci expressing 
serotype 37 CPS are virtually unable to form biofilms (Moscoso et al., 2006), so it was 
expected that the transformant would show a drastic reduction in biofilm-forming 
capacity compared to the encapsulated P192 parental strain (Fig. 2).  
Together, the above results indicate that, in addition to genetic background, the 
chemical composition/structure of the CPS is crucial to biofilm-forming capacity. A 
close comparison of the primary structures of the repeating units of the CPS of 
serotypes 19F and 19A on one hand, and 19B and 19C on the other, suggest that the 
disaccharides -D-Glcp-(1→2)--L-Rhap-(1→ and -D-Glcp-(1→3)--L-Rhap-(1→ 
(present in serotype 19F and 19A CPSs respectively, but not in 19B and 19C capsules) 
may be important for promoting biofilm formation.  
Biofilm-forming capacity of other pneumococcal CPSs with disaccharides similar to -
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D-Glcp-(1→3)--L-Rhap 
The disaccharide -D-Glcp-(1→3)--L-Rhap-(1→ is present in the CPS of the four 
known serotypes of serogroup 6 (Fig. 3A). Moreover, the CPSs of all four are 
characterized by the presence of a rhamnose–ribitol linkage. However, the CPSs of 6B 
and 6D have a 1→4 rhamnose–ribitol linkage, whereas those of 6A and 6C have a 1→3 
rhamnose–ribitol linkage; 6A and 6B CPSs also contain galactose, while those of 6C 
and 6D do not (Bratcher et al., 2010). 
We previously reported (Moscoso et al., 2006) that a serotype 6B clinical isolate and 
an M11 transformant expressing the 6B capsule showed some 70% of the biofilm-
forming capacity of the unencapsulated M11 strain. The analysis of other members of 
this serogroup, namely serotypes 6A and 6C (no serotype 6D isolate was available) 
showed that both clinical isolates and isogenic transformants expressing these capsules 
formed ≥40% of the quantity of biofilm formed by the nonencapsulated control strain 
(Fig. 3B). These results agree with the hypothesis that the presence of -D-Glcp-(1→3)-
-L-Rhap-(1→ in the CPS is strongly related to biofilm-forming capacity. 
Dob1 has long been recognised as a hybridoma-secreted human immunoglobulin G2 
antibody that binds to and opsonizes pneumococci of serogroup 6 (Sun et al., 1999). It 
can bind to synthetic capsular carbohydrates -D-Galp-(1→3)--D-Glcp-(1→3)--L-
Rhap-(1→3)-D-Rib-ol and -D-Glcp-(1→3)--L-Rhap-(1→3)-D-Rib-ol, but not to 
serotype 2 and 19F CPSs, which contain -D-Glcp-(1→3)--L-Rhap and -D-Glcp-
(1→2)--L-Rhap determinants respectively (Park et al., 2009). The epitope -D-Glcp-
(1→3)--L-Rhap is present in the CPS of serotypes 6A, 6B, 6C, 6D and 19A, but not in 
that of 19F. Purified Dob1 was added to strain P181 (a serotype 19A transformant) in a 
standard biofilm-forming assay. When Dob1 was used in amounts that did not cause 
growth inhibition, no changes in biofilm formation were seen (data not shown). 
The biofilm-forming capacity of serotypes 18A, 18B and 18C was also investigated. 
Serotype 18A CPS contains the disaccharide -D-GlcpNAc-(1→3)--L-Rhap-(1→, 
whereas serotypes 18B and 18C CPSs have -D-Glcp-(1→3)--L-Rhap-(1→, very 
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similar to those present in serogroups 6 and 19 (Fig. 4A). In addition, serotype 18C has 
a glycerol-phosphate substituent required for the antigenicity of the 18C CPS to be 
conserved (Chang et al., 2012). Among all the members investigated of this serogroup, 
only one clinical isolate of serotype 18C was able to form a substantial amount of 
biofilm, but the corresponding M11 transformant (strain P202) showed no significant 
biofilm-forming capacity (Fig. 4B).  
Discussion 
The antiphagocytic properties of S. pneumoniae CPS are essential for it to show 
systemic virulence (Hyams et al., 2010). At least 95 different pneumococcal serotypes 
are known, each with a biochemically distinct CPS. The most recent descriptions 
include serotypes 6E (Ko et al., 2013), 6F and 6G (Oliver et al., 2013a).  
It is likely that additional serotypes remain to be described (note that serological 
heterogeneity among serotype 20 isolates has recently been reported (Burton and Nahm, 
2012)). There is also growing evidence that pneumococci can change their CPS 
structure and, consequently, their immunological properties through minimal genetic 
modifications (Oliver et al., 2013b; Oliver et al., 2013a). The distribution of serotypes 
worldwide is also continuously evolving since it depends on the year, country, age of 
the individual and site of isolation, and use of antibiotics. The widespread use of PCV7 
for the immunization of children has strongly modified the prevalence of S. pneumoniae 
serotypes; those covered by PCV7 have declined while nonvaccine serotypes have 
become more common. In particular, the noticeable proliferation of multiresistant 19A 
pneumococci has been associated with PCV7 use (Hulten et al., 2013), although 
increases had been reported before the introduction of the vaccine (Dagan et al., 2009), 
perhaps as a result of antibiotic pressure (Hulten et al., 2013).  
The present results show that clinical isolates as well as isogenic pneumococcal 
transformants of serotypes 19F or 19A (but not those of serotypes 19B or 19C) are 
capable of forming substantial amounts of biofilm in vitro. Comparisons of the primary 
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structure of the repeating units of the corresponding CPSs suggest that the presence of 
disaccharides -D-Glcp-(1→2)--L-Rhap-(1→ (serotype 19F) and -D-Glcp-(1→3)--
L-Rhap-(1→ (serotype 19A) may stimulate biofilm formation in some way. In 
agreement with this idea, S. pneumoniae serogroup 6 strains, which also contain the 
latter disaccharide in their CPSs, were seen to be noticeable biofilm formers. The 
serogroup 18 isolates, however, showed no such behaviour. The CPS of serogroup 18 
pneumococci contains -L-Rhap instead of the -L-Rhap seen in the CPSs of serotypes 
19F/19A and serogroup 6.  
Other factors may also affect biofilm formation, e.g., the primary structure of an 
oligosaccharide and its three-dimensional folding. However, the binding of the Dob1 
antibody, which recognizes the critical epitope -D-Glcp-(1→3)--L-Rhap (Park et al., 
2009), did not modify the biofilm-forming capacity of a 19A pneumococcal strain, at 
least under the experimental conditions used here. 
The two serotypes that show the strongest colonization capacity, 19A and 6C (Laufer 
et al., 2010), are not covered by the PCV7 vaccine. Following the introduction of 
PCV7, serotype 19A has emerged as one of the most commonly encountered clinical 
serotypes (Hulten et al., 2013). It has been suggested that any effect of PCV7 on 19A 
would be limited to disease prevention once colonization has occurred, rather than any 
prevention of colonization itself (Hausdorff et al., 2010). The discovery of the strong 
colonization capacity of serotypes 19A and 6C should therefore be taken into account in 
the design of new pneumococcal conjugated vaccines. 
A 13-valent pneumococcal conjugate vaccine (PCV13) has recently been licensed for 
use in children and adults at risk or with immunocompromising conditions (Advisory 
Committee on Immunization Practices, 2012). PCV13 is identical in formulation to 
PCV7 but with six additional targets covered (1, 3, 5, 6A, 7F, and 19A). As observed 
for PCV7, the widespread use of PCV13 will likely produce a decline in IPD caused by 
the serotypes covered, as well as that inflicted by certain related serotypes, e.g., serotype 
6C (McEllistrem and Nahm, 2012). In fact, a recent study carried out in 8 children 
hospitals in the United States has shown that IPD decreased 42% overall and 53% for 
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children <24 months of age in 2011 compared with the 3 years before PCV13 use 
(Kaplan et al., 2013). Unfortunately, it remains unknown whether this vaccine can 
protect against infection by serotype 6D; the recent emergence of multidrug-resistant 
6D pneumococci is a cause of much concern (Ko et al., 2012). Other non-PCV13 
serotypes that appear to be rapidly increasing in prevalence include 24F (Ardanuy et al., 
2012), 35B (Richter et al., 2013), 33F, 22F, 12, 15B, 15C, 23A and 11 (Kaplan et al., 
2013). As shown in the present work, serotype 24F isolates do not usually form biofilms 
in vitro. The ability of serotypes 35B, 33F, 22F, 12, 15B, 15C, 23A and 11 
pneumococci to produce biofilms was not investigated. The huge variety of 
pneumococcal serotypes that exist warrants studies on non-PCV13 emerging serotypes, 
which should be carefully monitored. The capacity to form biofilms, which the present 
work shows can be rapidly tested in vitro, could help in predicting the expansion of 
post-PCV13 pneumococcal isolates. 
Experimental procedures 
Strains, plasmids, media and genetic transformation 
The pneumococcal strains of the different serotypes used in this study are listed in Table 
1. All strains were grown in C medium (Lacks and Hotchkiss, 1960) supplemented 
(C+Y medium), or not, with 0.08% yeast extract. The plasmid pDLP49, which encodes 
the Tts -glucosyltransferase of S. pneumoniae responsible for the synthesis of type 37 
CPS, has been previously described (Llull et al., 1999; Llull et al., 2001). S. 
pneumoniae was transformed with chromosomal or plasmid DNA by treating 
precompetent cells with 100 ng/mL of synthetic competence-stimulating pheromone 1 
at 37°C for 10 min to induce competence, followed by incubation at 30°C during DNA 
uptake. Encapsulated transformants of strain M11 were enriched by successive transfers 
of the transformed culture to C medium containing 0.08% bovine serum albumin, and 
supplemented with 0.5 L/mL of anti-R antiserum before plating (Mollerach et al., 
1998). Anti-R (antisomatic) antiserum contains group-specific agglutinins, which, at the 
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proper dilution, agglutinate only unencapsulated pneumococci. Serotyping by the 
capsular reaction (Quellung) was kindly performed by L. Vicioso (Spanish 
Pneumococcal Reference Laboratory, Majadahonda, Spain). 
Biofilm formation assay and quantification 
The optimal conditions for biofilm formation by pneumococcal cells have been 
previously described (Moscoso et al., 2006). In short, all biofilms were formed in 
Costar 3595 96-well PST microtiter plates (Corning). Cells were grown in CpH8 
medium to an optical density at 550 nm (OD550) of 0.5–0.6, sedimented by 
centrifugation, resuspended in an equal volume of CpH8 medium, and diluted 1/10. 
Two hundred microliter aliquots were dispensed into each well. After 6 h of incubation 
at 34°C, the biofilm formed was stained with 0.2% crystal violet and rinsed three times 
with distilled water to remove nonadherent bacteria. After solubilizing the biofilm in 
95% ethanol (200 μl per well), the OD595 was determined using an Anthos 2020 
microplate absorbance reader (Anthos Labtec Instruments).The human antibody Dob1 
was diluted 1/10 to 1/40 and used to test for the inhibition of biofilm formation was 
kindly provided by M. H. Nahm (University of Alabama at Birmingham, AL, USA). 
Multilocus Sequence Typing 
Multilocus sequence typing (MLST) was performed as described elsewhere (Enright 
and Spratt, 1998) with the tools provided by the MLST website (http://www.mlst.net). 
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Table 1. S. pneumoniae strains used. 
Strain Descriptiona Source or referenceb 
M11 R6 derivative (nonencapsulated) (Moscoso et al., 2006) 
CLINICAL   
    1037/10 19F; blood; ST9077 A. Fenoll; ISCIII 
    1064/10 19F; AOM; ST177 A. Fenoll; ISCIII 
    2567/10 19F; CSF; ST9078 A. Fenoll; ISCIII 
    2789/10 19F; BAA; ST9079 A. Fenoll; ISCIII 
    SSISP19F/1 19F Statens Serum Institut 
    G54 19F; ST63 (Moscoso et al., 2006) 
    1041/10 19A; blood; ST9065 A. Fenoll; ISCIII 
    1061/10 19A; AOM; ST9066 A. Fenoll; ISCIII 
    2797/10 19A; BAA; ST9080 A. Fenoll; ISCIII 
    2998/10 19A; CSF; ST2013 A. Fenoll; ISCIII 
    5086 19A; ST81 J. Liñares; IDIBELL 
    82220 19B; ST3492 Statens Serum Institut 
    82211 19C; ST9081 Statens Serum Institut 
    1356/12 6A; ST2467 A. Fenoll; ISCIII 
    1056/12 6B; ST179 A. Fenoll; ISCIII 
    1262/12 6C; ST386 A. Fenoll; ISCIII 
    840/12 18A; ST9082 A. Fenoll; ISCIII 
    910798 18B; ST113 H. Bootsma, Radboud Univ. 
    854/12 18C; ST9083 A. Fenoll; ISCIII 
    SSISP18C/1 18C; ST4706 Statens Serum Institut 
    2020/11 24F; ST230 A. Fenoll; ISCIII 
TRANSFORMANTS   
    P014 M11 transformed with SSISP18C/1 DNA 
(18C) 
This study 
    P015 M11 derivative (23Fc) (Moscoso et al., 2006) 
    P181 M11 transformed with 5086 DNA (19A) This study 
    P182 M11 transformed with 82220 DNA (19B) This study 
    P184 M11 transformed with 82221 DNA (19C) This study 
    P191 M11 transformed with 1064 DNA (19F) This study 
    P192 M11 transformed with G54 DNA (19F) This study 
  2 
    P194 P192 transformed with pDLP49 (19F/37; 
binary) 
This study 
    P198 M11 transformed with 1356/12 DNA (6A) This study 
    P199 M11 transformed with 1056/12 DNA (6B) This study 
    P200 M11 transformed with 1262/12 DNA (6C) This study 
    P201 M11 transformed with 840/12 DNA (18A) This study 
    P202 M11 transformed with 854/12 DNA (18C) This study 
    P224 M11 transformed with 2020 DNA (24F) This study 
    P230 M11 transformed with 910798 DNA (18B) This study 
a. AOM, acute otitis media, BAA, bronchoalveolar aspirate; CSF, cerebrospinal fluid.  
b. IDIBELL, Instituto de Investigación Biomédica de Bellvitge, Barcelona, Spain; 
ISCIII, Instituto de Salud Carlos III, Majadahonda (Madrid), Spain. 
c. This strain was originally reported as 19F. However, we have found that it actually 
corresponds to a 23F transformant (unpublished). 
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Figure Legends 
Fig. 1. Primary structures and antigenic formulae for the serotypes belonging to S. 
pneumoniae serogroup 19. 
The known structures of serogroup 7 CPSs are also shown for comparison. The initial 
sugar attached to the undecaprenyl phosphate lipid carrier is shown on the right. The 
trisaccharide common to all serogroup 19 polysaccharides is boxed. The predicted 7a 
antigen common to serogroup 7 pneumococci is shown in the dotted rectangle. The 
proposed disaccharide corresponding to the 7h antigen common to type serotypes 19B, 
19C and 7B is shown in the grey box. 
 
Fig. 2. Biofilm formation by encapsulated S. pneumoniae strains of serogroup 19. 
Clinical isolates of this serogroup were grown in C medium for 6 h at 34°C. Biofilm 
formation (solid bars) was quantified by staining with crystal violet. Grey bars 
correspond to biofilms developed by encapsulated transformants of the indicated 
serotype using the unencapsulated M11 strain as a recipient. The M11 strain was used 
as a control (open bar). Biofilm formation by encapsulated strains was normalized for 
absorbance, and the percentage normalized against the control strain M11. The 
percentages shown are the mean ± standard error of at least four independent 
experiments performed in triplicate. 
 
Fig. 3. Capsular polysaccharide and biofilm formation by encapsulated S. pneumoniae 
strains of serogroup 6. 
A. Primary structures of the CPS of the different serotypes of serogroup 6. The 
disaccharide shared with serotype 19A is marked in black.  
B. Biofilm formation assay. Growth conditions and biofilm quantification techniques 
were the same as for serogroup 19. Open bar - control strain M11; solid bars - clinical 
isolates; grey bars - encapsulated transformants of the indicated serotype using the 
unencapsulated M11 strain as a recipient. Biofilm formation by the encapsulated strains 
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was normalized for absorbance, and the percentage normalized against the control strain 
M11. The percentages shown are the mean ± standard error of at least three independent 
experiments performed in triplicate. 
 
Fig. 4. Capsular polysaccharides and biofilm formation by encapsulated S. pneumoniae 
strains of serogroup 18. 
A. Primary structures of capsular polysaccharides of the different serotypes of 
serogroup 18. A disaccharide very similar to the one present in serotype 19A is marked 
in black. 
B. Biofilm formation assay. Growth conditions and biofilm quantification techniques 
were the same as for serogroup 19. Open bar - control strain M11; solid bars - clinical 
isolates; grey bars - encapsulated transformants of the indicated serotype using the 
unencapsulated M11 strain as a recipient. Biofilm formation by the encapsulated strains 
was normalized for absorbance, and the percentage normalized against the control strain 
M11. The percentages shown are the mean ± standard error of at least three independent 
experiments performed in triplicate. 
 
 




